A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Purpose

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Conditions

  • Obesity
  • Overweight
  • Type 2 Diabetes

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening - Have type 2 diabetes - Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening - Have a history of at least one unsuccessful dietary effort to lose body weight

Exclusion Criteria

  • Have type 1 diabetes - Have an unstable body weight within 90 days prior to screening - Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening - Have acute or chronic hepatitis or pancreatitis - Are taking other medications or alternative remedies to manage weight loss

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Phase 3b
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Orforglipron Dose 1 		Participants will receive orforglipron orally
  • Drug: Orforglipron
    Administered orally
    Other names:
    • LY3502970
Experimental
Orforglipron Dose 2 		Participants will receive orforglipron orally
  • Drug: Orforglipron
    Administered orally
    Other names:
    • LY3502970
Experimental
Orforglipron Dose 3 		Participants will receive orforglipron orally
  • Drug: Orforglipron
    Administered orally
    Other names:
    • LY3502970
Experimental
Orforglipron Dose 4 		Participants will receive orforglipron orally
  • Drug: Orforglipron
    Administered orally
    Other names:
    • LY3502970
Placebo Comparator
Placebo 		Participants will receive placebo orally
  • Drug: Placebo
    Administered orally

Recruiting Locations

More Details

NCT ID
NCT06972472
Status
Active, not recruiting
Sponsor
Eli Lilly and Company

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center